J. Suggett

发表

Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review

Jolyon P. Mitchell, D. Coppolo, J. Schloss, 2021, Pulmonary Therapy.

Clinically Relevant In Vitro Testing of Orally Inhaled Products—Bridging the Gap Between the Lab and the Patient

Jolyon P. Mitchell, M. Nagel, J. Suggett, 2016, AAPS PharmSciTech.

Developing Ways to Evaluate in the Laboratory How Inhalation Devices Will Be Used by Patients and Care-Givers: The Need for Clinically Appropriate Testing

Jolyon P. Mitchell, J. Suggett, 2014, AAPS PharmSciTech.

A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP

B. Carlin, D. Coppolo, C. Burudpakdee, 2017, Pulmonary Therapy.

A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients

Huan Huang, D. Coppolo, C. Burudpakdee, 2018, Pulmonary Therapy.

Are valved holding chambers (VHCs) interchangeable? An in vitro evaluation of VHC equivalence.

E. Falaschetti, M. Nagel, S. Dissanayake, 2018, Pulmonary pharmacology & therapeutics.

Oscillating positive expiratory pressure (oPEP) therapy in chronic obstructive pulmonary disease and bronchiectasis

G. Parraga, S. Svenningsen, D. McCormack, 2014 .

COPD_A_256866 2527..2538

D. Coppolo, K. Wada, J. Suggett, 2020 .

Development and Evaluation of a Family of Human Face and Upper Airway Models for the Laboratory Testing of Orally Inhaled Products

Jolyon P. Mitchell, D. Coppolo, M. Nagel, 2017, AAPS PharmSciTech.

Evaluation of Count Accuracy of a Top-Mounted Dose Indicator for a Pressurized Metered-Dose Inhaler ( pMDI ) : A Study Involving Adult Participants Naïve to the Product

Jolyon P. Mitchell, J. Suggett, Peter Scarrott, 2014 .

Oscillatory Positive Expiratory Pressure (oPEP) Treatment in Chronic Obstructive Pulmonary Disease

G. Parraga, S. Svenningsen, M. Kirby, 2013 .

Hyperpolarized 3 He Magnetic Resonance Imaging following Oscillatory Positive Expiratory Pressure Treatment in GOLD stage II & III COPD

G. Parraga, S. Svenningsen, M. Kirby, 2012 .

Use of Enzymes in the Dissolution Testing of Gelatin Capsules and Gelatin-Coated Tablets— Revisions to Dissolution and Disintegration and Dissolution of Dietary Supplements

Erika S. Stippler, John C. Kraemer, M. Hussain, 2014 .

Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada

N. Thanh, P. Jacobs, A. Kaplan, 2019, Canadian respiratory journal.

Developing Ways to Evaluate in the Laboratory How Inhalation Devices Will Be Used by Patients and Care-Givers: The Need for Clinically Appropriate Testing

J. Suggett, J. Mitchell, 2014, AAPS PharmSciTech.

A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC

S. Dissanayake, J. Suggett, 2018, Therapeutic advances in respiratory disease.

Impact of Oscillating Positive Expiratory Pressure Device Use on Post-Discharge Hospitalizations: A Retrospective Cohort Study Comparing Patients with COPD or Chronic Bronchitis Using the Aerobika® and Acapella® Devices

D. Coppolo, K. Wada, J. Suggett, 2020, International journal of chronic obstructive pulmonary disease.

Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations

D. Coppolo, J. Suggett, S. Kowal, 2017, International journal of chronic obstructive pulmonary disease.

A practical guide for interpretation of ERS guidelines for methacholine challenge test (MCT)

M. Nagel, J. Suggett, 2018, Clinical Problems.

A Retrospective Study of the Effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for Asthma Control

D. Coppolo, C. Burudpakdee, J. Suggett, 2017, Pulmonary Therapy.

In vitro and clinical characterization of the valved holding chamber AeroChamber Plus® Flow-Vu® for administrating tiotropium Respimat® in 1-5-year-old children with persistent asthmatic symptoms.

M. Nagel, M. Engel, H. Wachtel, 2018, Respiratory medicine.

Development and Evaluation of a Family of Human Face and Upper Airway Models for the Laboratory Testing of Orally Inhaled Products

D. Coppolo, M. Nagel, J. Suggett, 2017, AAPS PharmSciTech.

In vitro and clinical characterization of the valved holding chamber AeroChamber Plus® Flow-Vu® for administrating tiotropium Respimat® in 1-5-year-old children with persistent asthmatic symptoms.

J. Suggett, G. El Azzi, Herbert Wachtel, 2018, Respiratory medicine.